Сроки действия патентов в США: обзор и особенности

none

Under United States patent law, the term of patent, provided that maintenance fees are paid on time, is 20 years from the filing date of the earliest U. S. or international (PCT) application to which priority is claimed (excluding provisional applications). The patent term in the United States was changed in 1995 to bring U. S. patent law into conformity with the World Trade Organization's Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) as negotiated in the Uruguay Round. As a side effect, it is no longer possible to maintain submarine patents in the U. S., since the patent term now depends on the filing date, not the issue date. Design patents have a shorter term than utility patents. Design patents filed on or after May 13, 2015, have a term of 15 years from issuance. Design patents filed prior to May 13, 2015, have a term of 14 years from issuance.

Even if the scope of a patent is narrowed, neither reissue nor reexamination changes the original expiration date. A reissued or reexamined patent expires on the day the original granted patent would have ordinarily expired. Example: The validity of a patent (filing: January 1, 2000; issue: January 1, 2002; end: January 1, 2020) is challenged. The USPTO issues a Certificate of Reexamination on January 1, 2004. The reexamined patent is in force until January 1, 2020, assuming payment of all maintenance fees.

The Drug Price Competition and Patent Term Restoration Act (Hatch Waxman Act) of 1984 provides patent holders on approved patented products with an extended term of protection under the patent to compensate for the delay in obtaining Food and Drug Administration (FDA) approval. Merck & Co., Inc. v. Hi Tech Pharmacal Co., Inc. ruled that patents extended under Hatch Waxman are still eligible to term extension. However, patents in force on June 8, 1995, solely because of the Hatch Waxman term adjustment are not eligible. Patent Term Adjustment (PTA) and Patent Term Extension (PTE) compensate a patent applicant for delays that occur during patent prosecution. Patent Term Adjustment (PTA) (see above) compensates applicants for USPTO caused delays; Patent Term Extension (PTE) compensates a patent owner for delays caused by the regulatory review (e. g. by FDA) before a product can be commercially marketed. PTA and PTE lengthen the term of the patent, theoretically permitting patent owners to enjoy more than 20 year patent term from the time of first non provisional filing.

A terminal disclaimer is a process by which a patent's term is shortened because it duplicates the claims of another patent which expires sooner. If any claim of a pending patent application would have been obvious in light of at least one claim of the applicant's issued patents, the USPTO may reject that claim for obviousness type double patenting and require the applicant to disclaim a part of the term of the pending application. For example, an applicant's patent A expires on December 24, 2000. The applicant filed another patent application two years later. Under some conditions, the second patent might expire later than the first (based upon the respective earliest claimed priority dates). If the applicant is required to file, and does file, a terminal disclaimer in the later filed patent, then the later filed patent will expire at the same time as the earlier filed patent, the extra term having been disclaimed ("terminal disclaimer"). In filing the terminal disclaimer, the later filed patent and the earlier filed patent must be, and remain, commonly owned. In the case of co pending applications, either or both of the applications may have claims rejected for obviousness type double patenting, and a terminal disclaimer may be required in either or both, in which case the earlier expiration date will control. After the Uruguay Round Agreements Act of 1994 (URAA), some patents with terminal disclaimers were eligible for a term adjustment because their referenced patents received a term adjustment under the URAA. Patents whose parents received extensions were eligible to file to receive a similar extension, because the claims they depended on were still protected. This has been discussed in the Manual of Patent Examining Procedure. A terminal disclaimer does not negate Patent Term Extension that has been granted under 35 U. S. C. 156. In a pharmaceutical patent dispute, Teva argued that Wyeth's patent on zaleplon drug products (Sonata) had expired because of a terminal disclaimer. Wyeth (and its exclusive licensee King) argued that patent's term was ongoing because of a Patent Term Extension due to FDA regulatory review delay. Under 35 U. S. C. 156(a), the term of a patent "shall be extended" after a series of provisions are satisfied. The district court found the language of the statute unambiguous and gives the court "no discretion". Thus, if the enumerated conditions are satisfied, the patentee is entitled to a term extension calculated pursuant to Section 156. Teva's motion to dismiss was consequently denied because "a terminally disclaimed patent is eligible for extension under [Section] 156." The case is interesting because the patentee in the first instance had expressly disclaimed term subsequent to 2003 to get the patent granted. However, the holding of this case does not apply to Patent Term Adjustment granted under 35 U. S. C. 154. Such term adjustments will be subject to any terminal disclaimer that has been filed. There is now a similar case wherein a company was given extension under S.156 and the generic entrant arguing against such extension between Merck and Hi tech for the drug dorzolamide (Trusopt). Here too, the first company (Merck) had filed a standard form terminal disclaimer. This patent was later given an extension and became the crux of the litigation.